| Human Immunodeficiency Virus |
2013-004809-24: The role of Home packs of HIV PEPSE in High Risk Individuals |
|
|
| Ongoing | 4 | 140 | Europe | Film-coated tablet, Celsentri (Trial Arm A), Truvada (Trial Arm A), Celsentri (Trial Arm B), Truvada (Trial Arm B) | Guy's & St. Thomas' NHS Foundation Trust, Viiv Healthcare UK Ltd, Gilead Sciences Ltd | HIV, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2014-004297-42: Effect of changing one medication (Atripla) to another (Eviplera) on functions of the brain and emotions Het effect van wisselen van het ene medicijn (Atripla) naar het andere medicijn (Eviplera) op de functies van de hersenen en emoties |
|
|
| Ongoing | 4 | 60 | Europe | Film-coated tablet, Eviplera, Atripla | UMC Utrecht, Gilead Sciences | neurocognitive and emotional functioning in HIV positive men using antiretroviral therapy neurocognitief en emotioneel functioneren bij HIV positieve mannen die antiretrovirale therapie gebruiken, brain functions and emotions with people infected with HIV who use anti-HIV medication. functies van het brein en emoties bij mensen geïnfecteerd met HIV die anti-HIV medicijnen gebruiken., Not possible to specify | | | | |
2015-003278-34: A RANDOMIZED BIOEQUIVALENCE STUDY OF EFAVIRENZ GENERIC DRUG AND SUSTIVA® (TABLETS 600 mg) IN PATIENTS WITH HIV-1 STUDIO RANDOMIZZATO PER LA VALUTAZIONE DELLA BIOEQUIVALENZA TRA EFAVIRENZ GENERICO E SUSTIVA® ENTRAMBI IN COMPRESSE DA 600 MG IN PAZIENTI CON HIV-1 |
|
|
| Not yet recruiting | 4 | 40 | Europe | Efavirenz, SUSTIVA, non applicabile, Film-coated tablet, EFAVIRENZ MYLAN - 600 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/PVDC/AL, SUSTIVA - 600 MG COMPRESSE FILM RIVESTITE 30 COMPRESSE IN BLISTER USO ORALE | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Mylan S.p.A. | Patients with HIV-1 Pazienti affetti da HIV-1, Patients with HIV-1 Pazienti affetti da HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
2011-003447-21: Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis |
|
|
| Ongoing | 4 | 280 | Europe | Maraviroc, Celsentri, Celsentri | Camden Provider Services, Pfizer | Prophylaxis and prevention of HIV Infection. | | | | |
2015-005297-37: Bone Evaluation in women over 40 who Switch from Truvada/NNRTI to Triumeq |
|
|
| Ongoing | 4 | 90 | Europe | Tenofovir, Lamivudine, Efavirenz, Nevirapine, Etravirine, Rilpivirine, Film-coated tablet, Tablet, Triumeq, Truvada, Atripla, Eviplera | King's College Hospital NHS Foundation Trust, ViiV Healthcare Ltd | Human Immunodeficiency Virus, People infected with Human Immunodeficiency Virus (HIV), Diseases [C] - Immune System Diseases [C20] | | | | |
2016-001371-69: Tenofovir DP concentrations in seminal cells and semen quality in HIV-1 infected patients receiving a TAF containing regimen Concentraciones de Tenofovir DP en células seminales y calidad del semen en pacientes infectados por el virus VIH-1 que reciben un régimen que contenga TAF |
|
|
| Ongoing | 4 | 15 | Europe | Coated tablet, Genvoya | Fundació Lluita contra la SIDA, Gilead Sciences S.L. | HIV-1 positive patients Pacientes VIH-1 positivos, HIV-1 positive patients Pacientes VIH-1 positivos, Diseases [C] - Virus Diseases [C02] | | | | |
2016-003345-29: Safety of tenofovir alafenamide (TAF) in patients who developed kidney toxicity while receiving tenofovir disoproxil fumarate (TDF) |
|
|
| Ongoing | 4 | 40 | Europe | Film-coated tablet, Descovy | Kings College Hospital NHS Foundation Trust, Gilead Sciences | HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02] | | | | |
2014-002284-15: A study to assess changes in Central Nervous System (CNS) function where no obvious symptoms exist, when switching from Atripla to Eviplera switch in HIV infected patients |
|
|
| Not yet recruiting | 4 | 40 | Europe | Eviplera, Film-coated tablet, Eviplera | St Stephen's AIDS Trust, Gilead Sciences Ltd | HIV, HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
| Not yet recruiting | 4 | 60 | Europe | Tivicay 50 mg film - coated tablets, Isentress 400 mg Film-coated Tablets, Truvada 200 mg/245 mg film-coated tablets, Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets, Film-coated tablet, Tivicay 50 mg film-coated tablets, Isentress 400 mg Film-coated Tablets, Truvada 200 mg/245 mg film-coated tablets, Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets | St Stephen's AIDS Trust, Merck, Sharp & Dohme Limited | HIV | | | | |
| Ongoing | 4 | 64 | Europe | Triumeq, Genvoya, Tablet, Triumeq, Genvoya | Fundación SEIMC-GESIDA, GILEAD Sciencies S.A. | HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2017-000469-62: Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients. DGT-SOT Ensayo clínico piloto de un brazo para evaluar la eficacia, las interacciones farmacocinéticas y la seguridad del dolutegravir más 2 inhibidores nucleósidos de la Transcriptasa Inversa (NRTIs en su siglas en inglés) en pacientes trasplantados de órganos sólidos infectados por el VIH-1. DGT-SOT |
|
|
| Ongoing | 4 | 20 | Europe | Triumeq 50 mg/600 mg/300 mg comprimidos recubiertos con película dolutegravir/abacavir/lamivudina, Tivicay 50 mg, Truvada comprimidos recubiertos con película., Coated tablet, Tablet, Triumeq®, Dolutegravir 50 mg, 200 mg de emtricitabina y 245 mg de tenofovir disoproxil (equivalente a 300 mg de tenofovir disoproxil fumarato ó 136 mg de tenofovir). | Fundació Clínic per a la Recerca Biomèdica, ViiV Healthcare | HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., Diseases [C] - Virus Diseases [C02] | | | | |
2017-002385-49: IN-UK-311-3956: A Feasibility Study of the Switch of Tenofovir disoproxil fumarate to Tenofovir alafenamide fumarate and the Effect on Kidney Function in individuals infected with both Chronic Hepatitis B and HIV. |
|
|
| Not yet recruiting | 4 | 20 | Europe | Descovy 200/10mg, Descovy 200/25mg, Film-coated tablet, Descovy 200/10mg, Descovy 200/25mg | King's College Hospital NHS Foundation Trust, Gilead Sciences International Ltd | HIV and Hepatitis B, HIV and Hepatitis B infections, Diseases [C] - Immune System Diseases [C20] | | | | |
2017-002855-27: BonE health in ageING Women: Improvement or prevention of changes in Bone MineralDensity by Switching Antiretroviral Agents. Is there an optimal time to intervene? La salute delle ossa nell¿invecchiamento femminile: miglioramento o prevenzione delle variazioni di densit¿ minerale ossea modificando i farmaci antiretrovirali. Esiste un momento ottimale per intervenire? |
|
|
| Not yet recruiting | 4 | 128 | Europe | truvada, stribild, eviplera, genvoya, descovy, Odefsey, J05AR03, eviplera, J05AR18, J05AR17, J05AR19, Film-coated tablet, TRUVADA - 30 COMPRESSE RIVESTITE CON FILM IN FLACONE HDPE DA 200 MG/245 MG, STRIBILD - 150MG/150MG/200MG/245MG/ - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EVIPLERA - 25MG RILPIVIRINA/200MG EMTRICITABINA/245MG TENOFOVIR DISOPROXIL-COMPRESSA RIVESTITA CON FILM-USO ORALE-FLACONE (HDPE) 30 COMPRESSE, GENVOYA - 150 MG / 150 MG / 200 MG /10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, DESCOVY - 200 MG/10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, ODEFSEY - 200 MG/25 MG/25 MG- COMPRESSA RIVESTITA- USO ORALE- FLACONE (HDPE) 30 COMPRESSE | UNIVERSITY HEALTH NETWORK, Gilead Sciences, Canadian HIV Trials Network | HIV infection and menopause infezione da HIV e menopausa, HIV infection and menopause infezione da HIV e menopausa, Diseases [C] - Virus Diseases [C02] | | | | |
2017-004137-91: A single-arm, open-label, multicenter phase IV trial to evaluate the efficacy and safety of elvitegravir / cobicistat / emtricitabine / tenofovir alfa-namide as first-line treatment in naïve patients with HIV-1 infection with severe immunosuppression Estudio fase IV, abierto, multicéntrico, de un único brazo para evaluar la eficacia y seguridad de elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida como tratamiento de primera línea en pacientes naïve con infección por VIH-1 con inmunosupresión severa |
|
|
| Ongoing | 4 | 50 | Europe | Tablet, Genvoya | Fundacion SEIMC-GESIDA, Gilead | AIDS SIDA, AIDS SIDA, Diseases [C] - Virus Diseases [C02] | | | | |
2018-000215-24: A trial to evaluate the immunogenicity of vaccine against human papillomavirus in HIV-infected men who have sex with men. GESIDA 10017 Study Ensayo clínico sobre la inmunogenicidad de la vacuna frente al virus del papiloma humano en hombres infectados por el VIH que tienen sexo con hombres. Estudio GESIDA 10017 |
|
|
| Ongoing | 4 | 166 | Europe | Suspension for injection in pre-filled syringe, Gardasil 9 | Fundacion SEIMC-GESIDA, Merck Sharp & Dohme | AIDS SIDA, AIDS SIDA, Diseases [C] - Immune System Diseases [C20] | | | | |
2016-000437-43: The time to protection and adherence requirements of Raltegravir with or without lamivudine in protection from HIV infection |
|
|
| Not yet recruiting | 4 | 36 | Europe | Raltegravir, Lamivudine, Tablet, Film-coated tablet, Raltegravir, Lamivudine | Guy's and St Thomas NHS Foundation Trust, Merck Sharp & Dhome Ltd | HIV, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos. |
|
|
| Ongoing | 4 | 100 | Europe | lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy | FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare | HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
| Ongoing | 4 | 110 | Europe | Symtuza, Tablet, Symtuza, Triumeq | Fundación SEIMC-GESIDA, JANSSEN CILAG S.A | HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2017-005033-22: How does changing antiretroviral therapy effect the progression of coronary atherosclerosis. |
|
|
| Not yet recruiting | 4 | 100 | Europe | Bictravy, EU/1/18//1289/001, Film-coated tablet, Bictravy | University of Liverpool, Gilead Pharmaceuticals, | Human immunodeficiency virus (HIV) and cardiovascular disease (CVD), Human immunodeficiency virus (HIV) and cardiovascular disease (CVD), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-004732-30: Will switching HIV-1-infected patients who have drug resistant HIV and stable on a regimen based on a protease inhibitor to another regimen based on the integrase inhibitor bictegravir be as equally effective? |
|
|
| Not yet recruiting | 4 | 100 | Europe | Bictegravir, Tenofovir alafenamide fumarate, Emtricitabine, Tablet, Bictegravir, Tenofovir alafenamide fumarate, Emtricitabine | University of Sussex, Gilead Pharmaceuticals | Human Immunodeficiency Virus, HIV, Body processes [G] - Immune system processes [G12] | | | | |
2019-000199-41: A study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in HIV+ patients. Estudio para evaluar el impacto del cambio de tratamiento antirretroviral de terapia dual a terapia triple sobre la inflamación en pacientes VIH + |
|
|
| Not yet recruiting | 4 | 234 | Europe | Bictarvy, Tivicay, Epivir, Tablet, Bictarvy, Tivicay, Epivir | Fundación SEIMC-GESIDA, Gilead Sciences, S.L | HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2019-002733-10: Exploratory, open-label, randomized clinical trial to assess the efficacy of first-line dual vs. triple antiretroviral therapy (art) in hiv-1 reservoir and in peripheral compartments in hiv-infected patients. Ensayo clínico abierto, aleatorizado para evaluar el efecto del tratamiento antirretroviral inicial doble vs.triple en el reservorio del VIH-1 y en tejidos periféricos en pacientes infectados por el VIH-1. |
|
|
| Ongoing | 4 | 44 | Europe | Coated tablet, Tivicay, Descovy, Lamivudine | FUNDACIÓ LLUITA CONTRA LA SIDA, Viiv Healthcare | HIV infection Infección por VIH, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
| Not yet recruiting | 4 | 80 | Europe | Stamaril, Powder and solvent for suspension for injection in pre-filled syringe, Stamaril | Aarhus University Hospital, Novo Nordisk Foundation | Healthy individuals or HIV-1 infected individuals, Healthy individuals or HIV-1 infected individuals, Body processes [G] - Immune system processes [G12] | | | | |
2020-000685-42: Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial. Proef ter vergelijking van twee HIV behandelingen en hun effect op het virus, de weerstand en metabole gezondheid. |
|
|
| Not yet recruiting | 4 | 134 | Europe | Biktarvy, Film-coated tablet, Dovato, Biktarvy | Ghent University Hospital, ViiV Healthcare, Ghent University Hospital | human immunodeficiency viruses (HIV), human immunodeficiency viruses (HIV), Diseases [C] - Virus Diseases [C02] | | | | |
| Not yet recruiting | 4 | 46 | Europe | Biktarvy, Triumeq, Film-coated tablet, Biktarvy, Triumeq | University of Sussex, Gilead Sciences | HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02] | | | | |
2019-004871-38: Evaluation of the benefits of immediate versus conventional treatment with BIC / FTC / TAF in naive patients with type 1 HIV infection Evaluación de los beneficios del tratamiento inmediato versus convencional con BIC/FTC/TAF en pacientes naives con infección por VIH tipo 1 |
|
|
| Not yet recruiting | 4 | 20 | Europe | Film-coated tablet, Biktarvy | FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE, INSTITUTO DE SALUD CARLOS III | HIV infection INFECCION POR VIH, HIV infection INFECCION POR VIH, Diseases [C] - Virus Diseases [C02] | | | | |
BIC-NOW, NCT06177574: Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: Clinical Trial |
|
|
| Completed | 4 | 208 | Europe | BIC/FTC/TAF | Carmen Hidalgo Tenorio, Gilead Sciences | HIV Infections | 10/23 | 10/23 | | |
2016-000087-42: Triumeq As an Integrase Single Tablet Regimen in People with HIV who Inject Drugs |
|
|
| Not yet recruiting | 4 | 50 | Europe | Triumeq, Film-coated tablet, Triumeq | University College Dublin, ViiV Healthcare | Human Immunodeficiency Virus (HIV) infection, HIV infection, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT02800655: Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy |
|
|
| Active, not recruiting | 4 | 100 | US | Digital Health Feedback System | University of California, San Diego, National Institute of Mental Health (NIMH), Gilead Sciences, ViiV Healthcare, GlaxoSmithKline, Proteus Digital Health, Inc. | HIV | 12/21 | 12/23 | | |
NCT04418037: DHFS for Medication Adherence Support During Hospital Admissions for Person Living With HIV |
|
|
| Active, not recruiting | 4 | 30 | US | Digital Health Feedback System(DHFS) | University of California, San Diego, National Institute of Mental Health (NIMH), Gilead Sciences, ViiV Healthcare | HIV/AIDS | 12/21 | 12/23 | | |
2021-005546-15: Simplified model using a mobile unit and a s test & treat approach among excluded population. Modelo simplificado que utiliza una unidad móvil y un enfoque de test and treat entre la población excluida. |
|
|
| Not yet recruiting | 4 | 100 | Europe | BIKTARVY, EMEA/H/C/004449, Coated tablet, BIKTARVY | Gileas Science, Gilead Science | HIV AIDS VIH SIDA, HIV and AIDS VIH y SIDA, Diseases [C] - Virus Diseases [C02] | | | | |
2022-000358-26: Safety, tolerability, and efficacy of a dose reduction strategy based on bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-infected adults. Seguridad, tolerabilidad y eficacia de una estrategia de reducción de dosis basada en bictegravir /emtricitabina / tenofovir alafenamida en adultos infectados por el VIH con supresión viral |
|
|
| Not yet recruiting | 4 | 40 | Europe | bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of emtricitabine, and tenofovir alafen, J05AR20, Coated tablet, Biktarvy 50 mg/200 mg/25 mg film-coated tablets | Institut d’Investigacions Biomèdiques August Pi i Sunyer, Instituto de Salud Carlos III (PI20/869) | HIV infection infección por HIV, HIV infection treatment tratamiento de Infecció por HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2021-005927-19: Clinical trial designed to evaluate the safety and convenience of switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir alafenamide in people with HIV, good control and neuropsychiatric vulnerabilities: MIND study Ensayo clínico para evaluar la seguridad y la conveniencia del cambio de Dolutegravir/Lamivudina por Bictegravir/Emtricitabina/Tenofovir alafenamida en personas con VIH, buen control y vulnerabilidades neuropsiquiátricas: Estudio MIND |
|
|
| Not yet recruiting | 4 | 80 | Europe | Biktarvy, Dovato, EU/1/18/1289/004, EU/1/19/1370/002, Tablet, Biktarvy, DOVATO | Fundación SEIMC-GESIDA, Gilead Sciences S.A | Human immunodeficiency virus Virus de la inmunodeficiencia humana, Human immunodeficiency virus Virus de la inmunodeficiencia humana, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04311957: Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults |
|
|
| Not yet recruiting | 4 | 386 | RoW | Continuation of boosted PI, B/F/TAF | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, Brigham and Women's Hospital, Harvard Medical School, Analysis Group, Inc., Weill Medical College of Cornell University | HIV-1-infection, Antiretroviral Therapy | 05/22 | 11/22 | | |
NCT05075070: Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected |
|
|
| Recruiting | 4 | 400 | RoW | Inactivated COVID-19 vaccine | China National Biotec Group Company Limited, Zhejiang Provincial Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd. | COVID-19, HIV Infections | 06/22 | 06/22 | | |
NCT05105295: Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected |
|
|
| Not yet recruiting | 4 | 400 | RoW | Inactivated COVID-19 vaccine | China National Biotec Group Company Limited, Zhejiang Provincial Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd. | COVID-19, HIV Infections | 06/22 | 06/22 | | |
NCT04334551: HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance |
|
|
| Recruiting | 4 | 40 | Canada, RoW | Doravirine | Clinique du Quartier Latin, Merck Frosst Canada Ltd. | HIV Infections | 07/22 | 10/22 | | |
2018-003458-26: Evaluating inflammatory and immunological changes of HIV-positive patients switching to DTG dual regimen compared to those switching to a triple drugs regimen (B/F/TAF). Valutazione dei cambiamenti a livello infiammatorio e immunologico nei pazienti con infezione da HIV che passano a un doppio regime terapeutico contenente DTG rispetto a quelli che passano a un triplo regime (B/F/TAF). |
|
|
| Not yet recruiting | 4 | 66 | Europe | lamivudina, dolutegravir, bictegravir/emtricitabina/tenofovir alafenamide fumarato, [3TC], [DTG], [B/F/TAF], Film-coated tablet, Biktarvy | AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, Gilead Sciences Inc. | HIV infection infezione da HIV, HIV infection infezione da HIV, Diseases [C] - Virus Diseases [C02] | | | | |
| Recruiting | 4 | 134 | Europe | Dual versus triple therapy in treatment of HIV-1 infection., not applicatble | University Hospital, Ghent, ViiV Healthcare | HIV-1-infection | 06/26 | 04/27 | | |
| Completed | 4 | 28 | US | B/F/TAF, Bictegravir/emtricitabine/tenofovir alafenamide | University of Maryland, Baltimore, Gilead Sciences | HIV-1-infection, Hepatitis B | 11/22 | 05/23 | | |
NCT05147740: Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age |
|
|
| Recruiting | 4 | 50 | US | B/F/TAF, Biktarvy® | Tulika Singh, MD, Gilead Sciences | HIV-1-infection | 12/22 | 12/22 | | |
NCT04296695: Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection |
|
|
| Active, not recruiting | 4 | 250 | RoW | B/F/TAF, Biktarvy, TDF/3TC/EFV, Tenofovir /Ravmidine /Efavirenz | Peking Union Medical College Hospital, Gilead Sciences | HIV-1-infection | 12/22 | 12/23 | | |
NCT05075044: Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected |
|
|
| Recruiting | 4 | 400 | RoW | Inactivated COVID-19 vaccine | China National Biotec Group Company Limited, Hubei Provincial Center for Disease Control and Prevention, Wuhan Institute of Biological Products Co., Ltd | HIV Infections, COVID-19 | 12/22 | 12/22 | | |
CHROME, NCT03823911: Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication |
|
|
| Completed | 4 | 87 | US | Elbasvir / Grazoprevir Oral Tablet [Zepatier], Sofosbuvir/Ledipasvir, Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Cardiac MRI | University of Maryland, Baltimore, National Institutes of Health (NIH), Merck Sharp & Dohme LLC | Cardiovascular Diseases, Hepatitis C, Hiv | 12/22 | 12/22 | | |
e-PrEP, NCT05528653: Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "" |
|
|
| Recruiting | 4 | 150 | US | Descovy | Vivent Health, Gilead Sciences | HIV Prevention | 07/24 | 07/24 | | |
| Completed | 4 | 520 | RoW | Switch to B/F/TAF, Biktarvy, Continue current regimen, Control | University of Nairobi, Gilead Sciences | HIV-1-infection | 04/23 | 03/24 | | |
| Terminated | 4 | 1 | Europe | BIKTARVY 50Mg-200Mg-25Mg Tablet | Chelsea and Westminster NHS Foundation Trust, Gilead Sciences, Imperial College London | Human Immunodeficiency Virus | 05/23 | 05/23 | | |
NCT03980223: Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men |
|
|
| Active, not recruiting | 4 | 637 | US | Doxycycline Hyclate Delayed-Release 200 mg | University of California, San Francisco, University of Washington, National Institute of Allergy and Infectious Diseases (NIAID), Mayne Pharma International Pty Ltd, San Francisco Department of Public Health | Gonorrhea, Chlamydia, Syphilis | 05/23 | 05/23 | | |
2020-001070-29: Efficacy, tolerability and acceptability of the single tablet regimen (STR) Biktarvy® by trans people living with HIV (TPLWH) Eficacia, tolerabilidad y aceptabilidad de régimen de un comprimido diario (STR) Biktarvy® en personas trans con VIH |
|
|
| Not yet recruiting | 4 | 50 | Europe | Biktarvy, Film-coated tablet, Biktarvy | Chelsea and Westminster NHS Foundation Trust, Gilead Sciences Inc. | Human Immunodeficiency Virus (HIV) infection Infección por el virus de la inmunodeficiencia humana (VIH), Human Immunodeficiency Virus (HIV) infection Infección por el virus de la inmunodeficiencia humana (VIH), Diseases [C] - Virus Diseases [C02] | | | | |
GLACIER, NCT04982445: Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) |
|
|
| Completed | 4 | 44 | US | CABENUVA | ViiV Healthcare | HIV Infections | 01/24 | 01/24 | | |
DYAD, NCT04585737: Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF |
|
|
| Completed | 4 | 222 | US | Dolutegravir / Lamivudine Pill, Dovato, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill, Biktarvy | Charlotte-Paige Rolle, MD, ViiV Healthcare | HIV I Infection | 08/23 | 08/23 | | |
NCT04442737: A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain |
|
|
| Completed | 4 | 103 | US | D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen | Janssen Scientific Affairs, LLC | HIV-1 | 08/23 | 08/23 | | |
NCT04079218: Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial |
|
|
| Completed | 4 | 51 | US | Estradiol Vaginal Insert, Vagifem®, Vagifem (estradiol vaginal tablet) | Albert Einstein College of Medicine, National Institute on Aging (NIA), Novo Nordisk A/S | HIV Infection, Vaginal Atrophy, Menopause, Menopause Related Conditions, Aging, Premature Aging, Atrophic Vaginitis, Dysbiosis, Vaginitis | 08/23 | 08/23 | | |
D2ARLING, NCT04549467: Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test |
|
|
| Completed | 4 | 244 | RoW | Lamivudine 300 MG, 3TC, dolutegravir, Emtricitabine / Tenofovir Disoproxil Pill, truvada | Fundacion IDEAA, ViiV Healthcare | Hiv, HIV-1-infection | 09/23 | 09/23 | | |
ReSTART, NCT04388904: Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. |
|
|
| Completed | 4 | 75 | US | Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC) | The Crofoot Research Center, Inc., Janssen Scientific Affairs, LLC | HIV-1-infection | 04/24 | 04/24 | | |
| Terminated | 4 | 10 | US | bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Biktarvy, Standard initiation of antiretroviral therapy (ART), Standard of Care ART | University of Colorado, Denver, Gilead Sciences | HIV/AIDS | 07/23 | 07/23 | | |
| Active, not recruiting | 4 | 40 | US | Dolutegravir/Lamivudine, Dovato | Saint Michael's Medical Center, ViiV Healthcare | Human Immunodeficiency Virus | 10/23 | 12/23 | | |
NCT05435209: Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents |
|
|
| Completed | 4 | 158 | RoW | Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Gardasil-4 | University of Washington, Merck Sharp & Dohme LLC | HPV Infection, HPV Vaccination | 10/23 | 10/23 | | |
NCT04982614: HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini |
|
|
| Active, not recruiting | 4 | 1403 | RoW | Gardasil ® 9, Human Papillomavirus 9-valent Vaccine, Recombinant, 9vHPV vaccine | Columbia University, Jhpiego, Merck Sharp & Dohme LLC | HPV Infection, Hiv, HPV Vaccine | 09/23 | 09/24 | | |
NCT04530630: Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant |
|
|
| Active, not recruiting | 4 | 20 | US | BIKTARVY 50Mg-200Mg-25Mg Tablet | Weill Medical College of Cornell University, Gilead Sciences | HIV Infections, Renal Transplant Rejection | 08/24 | 09/24 | | |
EPIC, NCT04669678: Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa |
|
|
| Completed | 4 | 108 | RoW | Etonogestrel (ETG) implant, Intramuscular depo-medroxyprogesterone acetate (IM DMPA), Sub-cutaneous medroxyprogesterone acetate (SC MPA), Non-hormonal intrauterine device (IUD) | University of Alabama at Birmingham, Merck Sharp & Dohme LLC, Wits Reproductive Health and HIV Institute, University of Washington | HIV Infections, Contraception, Drug-drug Interaction | 02/24 | 02/24 | | |
NCT03898856: Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients |
|
|
| Recruiting | 4 | 100 | US | Crofelemer, Diagnostic tests for cause of chronic diarrhea | The University of Texas Health Science Center, Houston, Napo Pharmaceuticals, Inc. | Chronic Diarrhea of Unknown Origin | 10/24 | 12/24 | | |
PILLAR, NCT05374525: A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States |
|
|
| Active, not recruiting | 4 | 116 | US | APRETUDE, Cabotegravir OLI | ViiV Healthcare | HIV Infections | 09/24 | 09/24 | | |
DGVTAF, NCT02656511: Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection |
|
|
| Active, not recruiting | 4 | 74 | US | Dolutegravir, Tivicay, Emtricitabine/Tenofovir, Truvada | University of California, San Francisco, ViiV Healthcare, Gilead Sciences | HIV | 05/27 | 05/28 | | |
| Recruiting | 4 | 120 | US | The Accelerate model of care, bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg | University of Missouri-Columbia, Gilead Sciences | HIV Infections, ART, Noncompliance, Patient | 05/25 | 11/25 | | |
| Recruiting | 4 | 230 | RoW | Intervention Arm: dolutegravir/lamivudine, Dovato, Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine) | Fundación Huésped, ViiV Healthcare, Federal University of Bahia | HIV-1-infection | 05/24 | 11/24 | | |
2023-001064-26: Cabotegravir + Rilpivirine Long-Acting Injection Rollover Study |
|
|
| Not yet recruiting | 4 | 710 | RoW | Rilpivirine, Cabotegravir, Prolonged-release suspension for injection, REKAMBYS, VOCABRIA | Janssen-Cilag International NV, Janssen-Cilag International NV | Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 1, Diseases [C] - Virus Diseases [C02] | | | | |
NCT06055543: Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients |
|
|
| Recruiting | 4 | 140 | Europe | Fortimel | Danone Specialized Nutrition | Malnutrition, Cancer, Inflammatory Bowel Diseases, Chronic Obstructive Pulmonary Disease (COPD), Hiv | 05/24 | 05/24 | | |
| Recruiting | 4 | 150 | US | Human papillomavirus 9-valent vaccine, recombinant, Gardasil-9 | Louisiana State University Health Sciences Center in New Orleans, Merck Sharp & Dohme LLC | Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection | 06/24 | 03/25 | | |
| Recruiting | 4 | 60 | Europe | DELSTRIGO 100Mg-300Mg-300Mg Tablet | Chelsea and Westminster NHS Foundation Trust, Merck Sharp & Dohme LLC | Hiv | 06/24 | 07/24 | | |
NCT05220358: Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study |
|
|
| Recruiting | 4 | 50 | US | Fostemsavir 600 MG [Rukobia] | Orlando Immunology Center, ViiV Healthcare | HIV-1-infection | 07/24 | 08/24 | | |
DeLiTE, NCT04665375: Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF? |
|
|
| Terminated | 4 | 4 | Canada | DOR/3TC/TDF, Delstrigo | University Health Network, Toronto, Merck Canada Inc. | Hiv, Weight Gain | 03/24 | 03/24 | | |
NCT06337032: A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments |
|
|
| Not yet recruiting | 4 | 350 | NA | F/TAF (High Dose Tablet), Descovy®, F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet), F/TAF (High Dose TOS), F/TAF (Low Dose TOS), F/TAF (Lowest Dose TOS), E/C/F/TAF, Genvoya®, E/C/F/TAF (Low Dose), Cobicistat (High Dose), GS-9350, Tybost®, Cobicistat (Low Dose), Cobicistat (TOS), B/F/TAF (High Dose), Biktarvy®, GS-9883/F/TAF, B/F/TAF (Low Dose), B/F/TAF (High Dose TOS), B/F/TAF (Low Dose TOS), B/F/TAF (Lowest Dose TOS), 3rd ARV Agent, Nucleos(t)ide reverse transcriptase inhibitors (NRTI), ATV, DRV, Lopinavir Boosted with ritonavir (LPV/r) | Gilead Sciences | HIV-1-infection | 03/34 | 03/34 | | |
EBONI, NCT05514509: A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories |
|
|
| Recruiting | 4 | 250 | US | APRETUDE, Cabotegravir tablet | ViiV Healthcare | HIV Infections | 09/25 | 09/25 | | |
NCT05549726: SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension |
|
|
| Active, not recruiting | 4 | 984 | RoW | Cabotegravir Injectable Suspension, Dynamic Choice Delivery Model, Standard of Care | University of California, San Francisco, Infectious Diseases Research Collaboration, Uganda, Makerere University, Kenya Medical Research Institute, University of California, Berkeley, National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Heart, Lung, and Blood Institute (NHLBI), ViiV Healthcare, University of Pittsburgh | HIV | 12/23 | 01/25 | | |
| Recruiting | 4 | 36 | Europe | Doravirine 100Mg Tab, pifeltro, Raltegravir 600Mg Tab, issentres, Biktarvy 50/200/25 Tab, biktarvy | Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Merck Sharp & Dohme LLC | Hiv | 11/24 | 12/24 | | |
NCT06104306: Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) |
|
|
| Recruiting | 4 | 35 | Europe, Canada, US | B/F/TAF, Biktarvy ® | Gilead Sciences | HIV-1-infection | 11/24 | 05/25 | | |
| Terminated | 4 | 2 | Canada | PrEP, Descovy® 200/25mg (DIN= 02454424), TAF/FTC, tenofovir alafenamide/emtricitabine, mHealth Model of Care, GoFreddie®, Standard of Care, PrEP standard of care | Unity Health Toronto, CIHR Canadian HIV Trials Network, Gilead Sciences | HIV Infections | 06/23 | 06/23 | | |
| Active, not recruiting | 4 | 555 | Europe | Dolutegravir/Lamivudine as a single pill, Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill. | Fundacion SEIMC-GESIDA, ViiV Healthcare | HIV-1-infection | 01/25 | 01/25 | | |
NCT05463783: Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain |
|
|
| Recruiting | 4 | 30 | US | Biktarvy, bictegravir/emtricitabine/tenofovir alafenamide, Symtuza, darunavir/cobicistat/emtricitabine/tenofovir alafenamide | East Carolina University, Janssen Scientific Affairs, LLC | HIV Infections, Obesity | 03/25 | 03/25 | | |
NCT05264662: Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant Women |
|
|
| Active, not recruiting | 4 | 511 | RoW | Adacel (Tdap) | Farzanah Laher, Sanofi | dTap Vaccine | 05/25 | 06/25 | | |
| Recruiting | 4 | 500 | US, RoW | Cabotegravir Injection [Apretude] | Beth Israel Deaconess Medical Center, Botswana Harvard AIDS Institute Partnership, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), ViiV Healthcare | Pre-Exposure Prophylaxis (PrEP), Breast Feeding | 08/27 | 08/27 | | |
| Active, not recruiting | 3b/4 | 831 | RoW | NRTIs, Nucleoside/Nucleotide Reverse Transcription Inhibitors, Dolutegravir, Tivicay, Darunavir, Prezista, Ritonavir, Norvir | Kirby Institute, UNITAID, National Institute of Allergy and Infectious Diseases (NIAID), National Health and Medical Research Council, Australia, ViiV Healthcare, Janssen Pharmaceutica | HIV Infections | 11/22 | 10/23 | | |
| Recruiting | 3b | 540 | RoW | Cabotegravir/Rilpivirine, Vocabria/Rekambys, Antiretroviral, 2NRTIs + dolutegravir 50mg once daily | MRC/UVRI and LSHTM Uganda Research Unit, Janssen Pharmaceuticals | HIV-1-infection | 11/24 | 11/25 | | |
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 |
|
|
| Active, not recruiting | 3 | 109 | US, Canada, Europe | TMC435, Pegylated interferon alpha-2a, Ribavirin | Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals | Hepatitis C Virus Genotype-1 | 08/13 | 08/13 | | |
NCT02131025: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen |
|
|
| Active, not recruiting | 3 | 428 | US, Canada | ABC/DTG/3TC FDC, Ongoing cART regimen | ViiV Healthcare, PPD, GlaxoSmithKline | Infection, Human Immunodeficiency Virus | 04/15 | 10/15 | | |
2014-003419-12: Switch from Efavirenz/Atripla to Rilpivirine Switch da Efavirenz/Atripla a Rilpivirina |
|
|
| Ongoing | 3 | 90 | Europe | EVIPLERA, ATRIPLA, Capsule, hard, EVIPLERA, ATRIPLA | AZIENDA OSPEDALIERA SAN GERARDO, MONZA, ITALIA, Gilead Sciences Srl | HIV INFECTION INFEZIONE DA HIV, HIV HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2011-004435-31: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc. |
|
|
| Ongoing | 3 | 12 | Europe | CELSENTRI 300mg Film coated tablets, CELSENTRI 300mg Film coated tablets | ViiV Healthcare UK Limited, VIIV HEALTHCARE UK LIMITED, ViiV Healthcare | HIV-1 infection | | | | |
| Active, not recruiting | 3 | 371 | Europe, Canada, US, RoW | BMS-663068, Placebo | ViiV Healthcare | HIV Infections | 08/16 | 12/25 | | |
2015-005045-31: Switching to tenofovir alafenamide fumarate or abacavir in patients with renal impairment due to tenofovir disoproxil fumarate. Overgaan naar tenofovir alafenamide fumaraat of abacavir bij patienten met een nierfunctieverslechtering door tenofovir disoproxil fumaraat. |
|
|
| Ongoing | 3 | 80 | Europe | FTC/TAF 200mg/10mg, FTC/TAF 200mg/25mg, Film-coated tablet, Tablet, Descovy, Kivexa | Erasmus MC, Gilead Sciences Inc | Renal safety of switching from TDF to TAF or ABC in patients with TDF-associated eGFR-decline. renale veiligheid van switchen van TDF naar TAF of ABC bij patienten met een TDF-geassocieerde eGFR-daling., Therapy of HIV Behandeling van HIV, Diseases [C] - Virus Diseases [C02] | | | | |
SWORD-1, NCT02429791 / 2014-005147-40: Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults |
|
|
| Completed | 3 | 510 | Europe, Canada, US, RoW | DTG 50 mg, RPV 25 mg, CAR | ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline | HIV Infections | 09/16 | 05/23 | | |
SWORD-2, NCT02422797 / 2014-005148-16: Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults |
|
|
| Completed | 3 | 518 | Europe, Canada, US, RoW | DTG 50 mg, RPV 25 mg, CAR | ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline | HIV Infections | 09/16 | 05/23 | | |
| Completed | 3 | 769 | NA | Doravirine, Darunavir, Ritonavir, TRUVADA™ or EPZICOM™/KIVEXA™ | Merck Sharp & Dohme LLC | HIV-1 | 09/16 | 03/23 | | |
2016-002413-22: Open label, Randomized clinical trial to evaluate switching from dual regimens to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients Studio in aperto, randomizzato, per valutare il passaggio da una terapia duplice ad una terapia con E/C/F/TAF in pazienti adulti HIV positivi con carica virale negativa. |
|
|
| Ongoing | 3 | 100 | Europe | Tivicay (dolutegravir), Emtriva, Lamivudina, Viread, Ziagen, Edurant, Intelence, Sustiva, Viramune, Film-coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Genvoya¿ 150 mg/150mg/200mg/10mg, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EMTRIVA - 30 CAPSULE RIGIDE IN BLISTER DA 200 MG, LAMIVUDINA MYLAN - 300 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/PVDC/AL, VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE, ZIAGEN - 300 MG COMPRESSE FILMRIVESTITE 6 BLISTER 10 COMPRESSE USO ORALE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE, INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE, SUSTIVA - 600 MG COMPRESSE FILM RIVESTITE 1 FLACONE 30 COMPRESSE USO ORALE, VIRAMUNE - 400 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - BLISTER (PVC/AL) 30 COMPRESSE | OSPEDALE SAN RAFFAELE, Gilead Sciences Inc. | HIV infection Infezione da HIV, HIV infected subjects pazienti affetti da virus HIV, Diseases [C] - Virus Diseases [C02] | | | | |
DRIVE-AHEAD, NCT02403674 / 2014-003382-17: Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) |
|
|
| Completed | 3 | 734 | NA | Doravirine, Tenofovir, Lamivudine, MK-1439A, ATRIPLA™, Placebo | Merck Sharp & Dohme LLC | Human Immunodeficiency Virus (HIV) | 03/17 | 09/23 | | |
2016-003741-29: Study of the use of anti_HIV drugs with reduced neuronal toxicity (including maraviroc) in patients with neurocogntive disorders Utilizzo di farmaci per il trattamento dell'infezione da HIV a ridotta tossicit¿ sui neuroni (incluso maraviroc) in pazienti con disturbi neurocognitivi |
|
|
| Not yet recruiting | 3 | 76 | Europe | CELSENTRI, EMTRIVA, MARAVIROC, EMTRIVA, Coated tablet, CELSENTRI - 300 MG COMPRESSA RIVESTITA CON FILM - USO ORALE BLISTER (PVC/ALU) 60 COMPRESSE, REZOLSTA - 800 MG/ 150 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE-FLACONE (HDPE)- 30 COMPRESSE, EMTRIVA - 30 CAPSULE RIGIDE IN FLACONE DA 200 MG | A.S.L. TO 2, Viiv Healthcare | HIV-infection, HIV-associated neurocognitive disorders Infezione da HIV, disordini neurocognitivi HIV-correlati, HIV-infection with neurocognitive problems Infezione da HIV con problemi neurocognitivi, Diseases [C] - Virus Diseases [C02] | | | | |
NCT03027297 / 2017-000285-30: TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV |
|
|
| Active, not recruiting | 3 | 133 | RoW | Darunavir, Ritonavir | Janssen Sciences Ireland UC, Janssen Research and Development | HIV-1 Infections | 12/17 | 12/18 | | |
DRIVE-SHIFT, NCT02397096 / 2014-005550-18: Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) |
|
|
| Completed | 3 | 673 | NA | Doravirine, Tenofovir, Lamivudine, Doravirine (PIFELTRO™), Doravirine/Lamivudine/Tenofovir disoproxil fumarate (DELSTRIGO™), MK-1439A, Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor, Baseline regimen of cobicistat-boosted elvitegravir, Baseline regimen of a non-nucleoside reverse transcriptase inhibitor, Baseline regimen of two nucleoside reverse transcriptase inhibitors | Merck Sharp & Dohme LLC | HIV-1 Infection | 02/18 | 09/23 | | |
ATLAS, NCT02951052 / 2016-001647-39: Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults |
|
|
| Active, not recruiting | 3 | 618 | Europe, Canada, US, RoW | Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI | ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline | Infection, Human Immunodeficiency Virus, HIV Infections | 05/18 | 12/26 | | |
FLAIR, NCT02938520 / 2016-001646-25: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants |
|
|
| Active, not recruiting | 3 | 631 | Europe, Canada, Japan, US, RoW | Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet | ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline | HIV Infections | 08/18 | 12/26 | | |